Serina Therapeutics, Inc.

Serina Therapeutics, Inc. announced that its stockholders approved an increase in authorized common stock from 40,000,000 to 125,000,000 shares at the 2026 Annual Meeting. Stockholders also approved an amendment to the 2024 Equity Incentive Plan to add 2,000,000 shares, and approved proposals related to the conversion of Series A Preferred Stock and the issuance of common stock for Private Placement Securities. Additionally, three directors were re-elected, and Frazier & Deeter, LLC was ratified as the independent auditor.

Serina Therapeutics announced its Phase 1b registrational clinical study of SER-252 for advanced Parkinson’s disease is underway, with TFL data from the SAD study arm targeted for the first half of 2027. The company also closed a $21.2 million private placement financing to support the advancement of SER-252. For the first quarter ended March 31, 2026, Serina reported a net loss of $6.9 million and held $24.5 million in cash and cash equivalents.

Serina Therapeutics reported a net loss of $6.9 million for the first quarter ended March 31, 2026, an increase from a $4.8 million net loss in Q1 2025. The company also provided key business updates, including the ongoing Phase 1b registrational clinical study of SER-252 for advanced Parkinson's disease, with TFL data from the SAD arm targeted for the first half of 2027. Additionally, Serina successfully closed a $21.2 million private placement financing in March and April 2026, significantly strengthening its balance sheet with cash and cash equivalents totaling $24.5 million as of March 31, 2026.

Serina Therapeutics reported a net loss of $6.9 million for Q1 2026, an increase from $4.8 million in Q1 2025, with a basic and diluted net loss per common share of $(0.58). Despite increased operating expenses, the company significantly boosted its cash and cash equivalents to $24.5 million and moved from a stockholders' deficit to $17.6 million in equity, primarily through $26.0 million in financing activities. These activities included a March 2026 PIPE and at-the-market sales. However, management expressed substantial doubt about the company's ability to continue as a going concern, as current capital is not expected to cover anticipated operating needs for the next 12 months.

Serina Therapeutics, Inc. (SER) announced its Annual Meeting of Stockholders to be held virtually on June 17, 2026. Key proposals include the election of three Class III directors, a significant increase in authorized common stock from 40 million to 125 million shares, and an increase of 2 million shares for the 2024 Equity Incentive Plan. Stockholders will also vote on the issuance of common stock related to Series A Preferred Stock conversion and Private Placement Securities exercise, advisory votes on executive compensation, and the ratification of auditors.

Serina Therapeutics, Inc. announced its Annual Meeting of Stockholders to be held virtually on June 17, 2026. Key proposals include increasing authorized common stock from 40 million to 125 million shares and increasing the 2024 Equity Incentive Plan share reserve by 2 million shares. Shareholders will also vote on the election of three Class III directors, approval of common stock issuances related to Series A Preferred Stock conversion and Private Placement Securities exercise, and advisory votes on executive compensation and its frequency.

Serina Therapeutics, Inc. has amended and restated its bylaws, updating the foundational rules governing the company's operations. The revised bylaws detail provisions for the company's registered and other offices, the potential adoption of a corporate seal, and comprehensive procedures for stockholders' meetings. Key updates include the Board's discretion to hold meetings solely by remote communication and specific requirements for stockholders to make nominations or submit other business at annual meetings.